Clinical trials: GBM, active
Glioblastoma, Glioblastoma Multiforme
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
Primary brain cancer kills up to 10,000 Americans a year. These brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination.
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioma, Malignant, GBM
- Trial name
- NCT05271240
- Testing
- Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation, Temozolomide and Radiation Alone
- Where
- United States
- Volunteers
- 432 people
- Sponsor
- Northwell Health
Newly Diagnosed MGMT Unmethylated Glioblastoma
D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
The purpose of this research study is to determine the safety and efficacy of administering a single intracerebral (within the brain) dose of investigational compounds called D2C7-immunotoxin (IT) and 2141-V11 in residual disease…
- Trial name
- NCT05734560
- Testing
- D2C7-IT, 2141-V11
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Darell Bigner
Glioblastoma
Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM
The purpose of this study is to test the effectiveness (how well the drug works), safety and tolerability of an investigational drug called nivolumab (also known as BMS-936558) in glioblastoma (a malignant tumor, or GBM), when…
- Trial name
- NCT03452579
- Testing
- Nivolumab, Standard Dose Bevacizumab, Low Dose Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- David Peereboom
High Grade Glioma, MGMT-Unmethylated Glioblastoma
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
This is a multicenter, open-label study of DB107-RRV (formerly Toca 511) and DB107-FC (formerly Toca FC) when administered following surgical resection in newly diagnosed High Grade Glioma (HGG) patients.
- Conditions
- High Grade Glioma, MGMT-Unmethylated Glioblastoma, MGMT-Methylated Glioblastoma
- Trial name
- NCT06504381
- Testing
- DB107-RRV, DB107-FC, Radiation Therapy (RT)
- Where
- 5 sites in United States
- Volunteers
- 70 people
- Sponsor
- University of California, San Francisco
Glioblastoma (GBM)
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
The goal of this clinical trial is to learn if DOC1021 + pIFN alongside standard of care (SOC) will improve survival in adult patients newly diagnosed with glioblastoma (IDH-wt).
- Trial name
- NCT06805305
- Testing
- DOC1021, Tumor resection, Temodar (Temozolomide)
- Where
- 18 sites in United States
- Volunteers
- 180 people
- Sponsor
- Diakonos Oncology Corporation
Glioblastoma Multiforme, Anaplastic Astrocytoma
Study of Pembrolizumab and M032 (NSC 733972)
This Phase I (Cohort I and Cohort II) and Phase II trial is designed to confirm the safety and tolerability of Pembrolizumab when given in conjunction with M032, an Oncolytic Herpes Simplex Virus (oHSV) that expresses IL-12 and…
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliosarcoma
- Trial name
- NCT05084430
- Testing
- M032, Pembrolizumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Alabama at Birmingham
Glioblastoma
Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma
This is an open-label, single-arm, dose-escalation and multiple-dose study to evaluate the safety, tolerability, and preliminary efficacy of TX103-CAR-T Cell Injection, a B7-H3-targeting chimeric antigen receptor T-cell (CAR-T)…
- Trial name
- NCT05241392
- Testing
- B7-H3-targeting CAR-T cells/TX103-CAR-T Cell Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Tiantan Hospital
Brain Tumor Adult
Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma
This study is being conducted to find out if the safety and tolerability of an experimental cell therapy is safe to administer to patients with a newly diagnosed glioblastoma multiforme (GBM) in combination with temozolomide…
- Trial name
- DRI (NCT04165941)
- Testing
- DRI cell therapy
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Clear Cell Renal Cell Carcinoma and Glioblastoma
Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma
A prospective, open-label, phase 1 study. This clinical trial aims to evaluate the diagnostic value of 68Ga-XT771, a CAIX/CAXII protein-specific probe, in PET/CT imaging for patients with clear cell renal cell carcinoma and…
- Trial name
- NCT07067905
- Testing
- 68Ga-XT771
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Chinese PLA General Hospital
Glioblastoma
Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma
This is a phase IB/II, open-label study evaluating CTX-009 as monotherapy and in combination with CTX-471. The study evaluates the safety and efficacy of the monotherapy and the combination in patients with recurrent…
- Trial name
- NCT07392957
- Testing
- CTX-009, CTX-471
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Washington University School of Medicine
Recurrent High Grade Gliomas, Glioblastoma (GBM)
A Study of SRN-101 Gene Therapy in Adults With Recurrent High-Grade Glioma (ALERT-1)
ALERT-1 is a Phase 1/2 study evaluating the safety and preliminary anti-tumor activity of SRN-101, an investigational gene therapy, in adults with recurrent high-grade glioma. High-grade glioma is a type of brain cancer.
- Conditions
- Recurrent High Grade Gliomas, Glioblastoma (GBM), Astrocytoma, Oligodendroglioma
- Trial name
- ALERT-1 (NCT07902037)
- Testing
- SRN-101
- Volunteers
- 40 people
- Sponsor
- Siren Biotechnology
Glioblastoma Multiforme
Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme
This study will collect blood and urine samples from patients undergoing radiation therapy for glioblastoma multiforme (a type of brain tumor) to investigate the effects of this treatment on blood cells and certain proteins.
- Trial name
- NCT00083512
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma
CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM
This is an open-label phase 1 study to assess the safety and feasibility of autologous T cells co-expressing two CARs targeting the cryptic EGFR epitope 806 and IL13Ra2 (referred to as "CART-EGFR-IL13Ra2 cells") in patients with…
- Trial name
- NCT05168423
- Testing
- CART-EGFR-IL13Ra2 Cells
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- University of Pennsylvania
Glioblastoma, Malignant Glioma
CARv3-TEAM-E T Cells in Glioblastoma
The goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for treating participants with glioblastoma.
- Conditions
- Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Glioma
- Trial name
- NCT05660369
- Testing
- CARv3-TEAM-E T cells
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Marcela V. Maus, M.D.,Ph.D.
Recurrent Malignant Glioma, Glioblastoma
Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas
GLIOTARG trial is a large single-center observational cohort study designed to investigate chemotherapy and targeted therapy outcomes in recurrent malignant gliomas.
- Conditions
- Recurrent Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma, Pleomorphic Xanthoastrocytoma
- Trial name
- GLIOTARG (NCT07448480)
- Testing
- Bevacizumab-Containing Regimens, Non-Bevacizumab Regimens, BRAF ± MEK Targeted Therapy
- Where
- Russia
- Volunteers
- 1,000 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Grade II Glioma, Grade III Glioma
Implantable Microdevice In Primary Brain Tumors
This pilot study will assess the safety and feasibility of using an implantable microdevice to measure local intratumor response to chemotherapy and other clinically relevant drugs in malignant brain tumors.
- Conditions
- Grade II Glioma, Grade III Glioma, Grade IV Glioma, Astrocytoma
- Trial name
- NCT04135807
- Testing
- Microdevice
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Oliver Jonas
Glioblastoma, Glioblastoma Multiforme (GBM)
The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab
This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in…
- Trial name
- GUAVA (NCT07052877)
- Testing
- PSMA PET/CT scan
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Royal North Shore Hospital
Astrocytoma, Glioblastoma
Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
This phase I/Ib trial tests the safety, side effects, and best dose of mycophenolate mofetil in combination with temozolomide and/or radiation therapy (standard of care) in treating patients with glioblastoma.
- Conditions
- Astrocytoma, Glioblastoma, Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
- Trial name
- NCT05236036
- Testing
- Mycophenolate Mofetil, Quality-of-Life Assessment, Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 86 people
- Sponsor
- Northwestern University
Glioma, Glioblastoma
Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile®
This is a phase 2, open-label clinical trial determining feasibility, safety, and tolerability of GammaTile® in elderly or frail subjects with newly diagnosed or recurrent malignant gliomas.
- Conditions
- Glioma, Glioblastoma, GBM, Glioma, Malignant
- Trial name
- ENDURANCE (NCT07821112)
- Testing
- GammaTile®
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, Irvine
Glioblastoma Multiforme, Relapse
Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma
The standard of care for glioblastoma (GBM) treatment involves maximal resection followed by concomitant radiotherapy and temozolomide.
- Trial name
- NCT06356883
- Testing
- IA Carboplatin + IA Caelyx, IA Carboplatin + IA Etoposide Phosphate
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Université de Sherbrooke